KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts

British Journal of Haematology

Volumn 155, Issue 3, 2011, Pages 328-339

  Miki, Hirokazu ^a   Ozaki, Shuji ^a,b   Nakamura, Shingen ^a   Oda, Asuka ^a   Amou, Hiroe ^a   Ikegame, Akishige ^a   Watanabe, Keiichiro ^a   Hiasa, Masahiro ^a   Cui, Qu ^a   Harada, Takeshi ^a   Fujii, Shiro ^a   Nakano, Ayako ^a   Kagawa, Kumiko ^a   Takeuchi, Kyoko ^c   Yata, Ken ichiro ^a   Sakai, Akira ^d   Abe, Masahiro ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Multiple myeloma; Osteoclast; Severe combined immunodeficient mouse; Spicamycin

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTI MYELOMA ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G1 PHASE; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOCLASTS; PURINE NUCLEOSIDES; RABBITS; RANDOM ALLOCATION; STROMAL CELLS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053987418     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08844.x     Document Type: Article

References (41)

1. Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D. & Matsumoto, T. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood, 100, 2195-2202.
2. Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D. & Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484-2491.
3. Asagiri, M. & Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone, 40, 251-264.
4. Barlogie, B., Attal, M., Crowley, J., van Rhee, F., Szymonifka, J., Moreau, P., Durie, B.G. & Harousseau, J.L. (2010) Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. Journal of Clinical Oncology, 28, 1209-1214.
5. Bar-Shavit, Z., Teitelbaum, S.L. & Kahn, A.J. (1983) Saccharides mediate the attachment of rat macrophages to bone in vitro. Journal of Clinical Investigation, 72, 516-525.
6. Burger, A.M., Kaur, G., Hollingshead, M., Fischer, R.T., Nagashima, K., Malspeis, L., Duncan, K.L. & Sausville, E.A. (1997) Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Clinical Cancer Research, 3, 455-463.
7. Byrd, J.C., Lucas, D.M., Mone, A.P., Kitner, J.B., Drabick, J.J. & Grever, M.R. (2003) KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood, 101, 4547-4550.
8. Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J. & Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641-2649.
9. DiLorenzo, L., Kobierski, L., Moore, K.A. & Borsook, D. (2002) A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain. Neuroscience Letters, 330, 37-40.
10. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
11. Elbein, A.D. (1987) Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annual Review of Biochemistry, 56, 497-534.
12. Hayakawa, Y., Nakagawa, M., Kawai, H., Tanabe, K., Nakayama, H., Shimazu, A., Seto, H. & Otake, N. (1983) Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells. The Journal of antibiotics (Tokyo), 36, 934-937.
13. Kamishohara, M., Kawai, H., Odagawa, A., Isoe, T., Mochizuki, J., Uchida, T., Hayakawa, Y., Seto, H., Tsuruo, T. & Otake, N. (1993) Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. The Journal of antibiotics (Tokyo), 46, 1439-1446.
14. Kamishohara, M., Kawai, H., Sakai, T., Isoe, T., Hasegawa, K., Mochizuki, J., Uchida, T., Kataoka, S., Yamaki, H., Tsuruo, T. & Otake, N. (1994) Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncology Research, 6, 383-390.
15. Kamishohara, M., Kawai, H., Sakai, T., Uchida, T., Tsuruo, T. & Otake, N. (1996) Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer Chemotherapy and Pharmacology, 38, 495-498.
16. Kamishohara, M., Kenney, S., Domergue, R., Vistica, D.T. & Sausville, E.A. (2000) Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500. Experimental Cell Research, 256, 468-479.
17. Kawasaki, K., Murakami, T., Ita, M., Sasaki, K. & Furukawa, S. (2000) KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells. Cytometry, 39, 211-216.
18. Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 2962-2972.
19. Lee, Y.S., Nishio, K., Ogasawara, H., Funayama, Y., Ohira, T. & Saijo, N. (1995) In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Research, 55, 1075-1079.
20. Lee, A.H., Iwakoshi, N.N., Anderson, K.C. & Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9946-9951.
21. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M. & Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783-1792.
22. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, Jr, W.J., Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907-4916.
23. Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D. & Matsumoto, T. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106, 3160-3165.
24. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
25. Ron, D. & Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology, 8, 519-529.
26. Sakai, T., Kawai, H., Kamishohara, M., Odagawa, A., Suzuki, A., Uchida, T., Kawasaki, T., Tsuruo, T. & Otake, N. (1995) Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives. The Journal of antibiotics (Tokyo), 48, 1467-1480.
27. Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M. & Matsumoto, T. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Research, 67, 1184-1192.
28. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
29. Stine, K.C., Warren, B.A., Saylors, R.L. & Becton, D.L. (2000) KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts. Leukemia Research, 24, 741-749.
30. Supko, J.G., Eder, Jr, J.P., Ryan, D.P., Seiden, M.V., Lynch, T.J., Amrein, P.C., Kufe, D.W. & Clark, J.W. (2003) Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clinical Cancer Research, 9, 5178-5186.
31. Suzuki, T., Suzuki, S.T., Yamada, I., Koashi, Y., Yamada, K. & Chida, N. (2002) Total synthesis of spicamycin. Journal of Organic Chemistry, 67, 2874-2880.
32. Takama, H., Tanaka, H., Sudo, T., Tamura, T. & Tanigawara, Y. (2001) Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer Chemotherapy and Pharmacology, 47, 404-410.
33. Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H., Nakamura, S., Nakano, A., Kagawa, K., Yata, K., Ozaki, S. & Matsumoto, T. (2010) Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE, 5, e9870.
34. Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. & Munshi, N.C. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 106, 713-716.
35. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142.
36. Wuilleme-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.L., Amiot, M. & Bataille, R. (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia, 19, 1248-1252.
37. Yamamoto, N., Tamura, T., Kamiya, Y., Ono, H., Kondoh, H., Shirao, K., Matsumura, Y., Tanigawara, Y. & Shimada, Y. (2003) Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. Japanese Journal of Clinical Oncology, 33, 302-308.
38. Yata, K. & Yaccoby, S. (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia, 18, 1891-1897.
39. Yoshida, H., Oku, M., Suzuki, M. & Mori, K. (2006) pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. Journal of Cell Biology, 172, 565-575.
40. Zhang, W.J., Ohnishi, K., Yoshida, H., Pan, L., Maksumova, L., Muratkhodjaev, F., Luo, J.M., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Shinjo, K., Takeshita, A. & Ohno, R. (2000) Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. Japanese Journal of Cancer Research, 91, 604-611.
41. Zhang, B., Gojo, I. & Fenton, R.G. (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 99, 1885-1893.